Efficacy and Safety Study of YH16410 Versus Rosuvastatin and Telmisartan Monotherapies in Patients With Hypertension and Hyperlipidemia

Model scores of the 29,894 trials active now.

Model score 5% for any early termination, 1% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 14% of the time (493 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2014-06-30. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: riskwomensubjectcoronaryiii
  Phrases that lowered it: and safetyefficacy andsafety ofevaluateblood pressure
• Sponsor's past termination rate: 0% (lowers risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Minimum age: 19 (lowers risk) · Who can join
• Phase: 3 (lowers risk) · Design
• Drug's FAERS reports marked serious: 60.2% (lowers risk) · Drug's FDA history
• Drug's FAERS reports with a death: 4.3% (lowers risk) · Drug's FDA history
• Design: parallel (raises risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Number of arms: 4 (lowers risk) · Design
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Has a data monitoring committee: No (lowers risk) · Design
• Blinding: quadruple (lowers risk) · Design
• Trials the sponsor started in the prior 2 years: 20 (lowers risk) · Sponsor's track record
• Drug's FAERS reports before start: 58391 (lowers risk) · Drug's FDA history
• Sponsor's past trials: 15 (lowers risk) · Sponsor's track record
• Disease area, neurology: No (lowers risk) · Disease area
• Primary purpose: treatment (raises risk) · Design
• Drug's FAERS reports in the prior 12 months: 8948 (lowers risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Clinical Trial to Evaluate the Efficacy and Safety of YHP1701 NCT03103256 · started 2017 · scored riskier than 8% of active trials completed
• Evaluating the Efficacy and Safety of Co-administrated Rosuvastatin/Ezetimibe and Telmisartan NCT03872232 · started 2019 · scored riskier than 4% of active trials completed
• Study to Evaluate the Efficacy and Safety of Telmisartan/Amlodipine/Rosuvastatin NCT03088254 · started 2016 · scored riskier than 5% of active trials completed
• Clinical Trial of Temisartan/Amlodipine & Rosuvastatin in Subjects With Hypertension and Hyperlipidemia NCT03067688 · started 2017 · scored riskier than 5% of active trials completed
• Efficacy & Safety Study of YH22162 vs Telmisartan/Amlodipine in Patients With Hypertension Inappropriately Controlled on Telmisartan/Amlodipine Treatment NCT02620163 · started 2015 · scored riskier than 5% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.